Lumvoa gains FDA approval for thyroid eye disease, adding an IGF-1R antagonist supported by phase 3 active and chronic TED trials.
FDA has
“With the approval of Lumvoa, we take a significant step forward in providing a meaningful treatment option for people living with thyroid eye disease,” said
Lumvoa is indicated in the United States for treating TED, an autoimmune orbital disorder associated with inflammation and tissue remodeling behind and around the eye.¹ Clinically, TED may cause proptosis, diplopia, pain, exposure symptoms, and, in severe cases, vision-threatening optic neuropathy.¹,² The approval was granted under priority review, and the drug previously received breakthrough therapy designation, according to Viridian.¹
The biologic is
The Lumvoa approval is based on THRIVE, a pivotal phase 3 trial in active TED, and THRIVE-2, a pivotal phase 3 trial in chronic TED.¹ According to the company, both studies met their primary and secondary end points, with statistically significant improvements at week 15 across key signs and symptoms of TED. The company reported reductions in proptosis as early as 3 weeks and stated that Lumvoa showed statistically significant effects on diplopia response and complete resolution of diplopia in both active and chronic TED.¹
The company did not disclose detailed trial sample sizes, absolute response rates, comparator data, or confidence intervals in its announcement. Until full peer-reviewed publication and FDA review documents are available, interpretation of the magnitude and durability of benefit will depend largely on the prescribing information and eventual trial manuscripts.
TED management has historically relied on risk-factor modification, control of thyroid dysfunction, local supportive care, corticosteroids for active inflammatory disease, orbital radiotherapy in selected cases, and rehabilitative surgery for inactive disease.² European Group on Graves’ Orbitopathy guidelines recommend treatment selection according to disease activity, severity, comorbidity, and patient priorities, with intravenous glucocorticoids remaining an established option for moderate-to-severe active disease.²
Biologic treatment in TED began with teprotumumab, an IGF-1R inhibitor evaluated in randomized trials in active moderate-to-severe disease. In a phase 2 trial, teprotumumab was shown to improve the composite response of proptosis and clinical activity score vs placebo.³ In the phase 3 OPTIC trial, teprotumumab produced a significantly higher proptosis response than placebo at week 24, with diplopia and quality-of-life improvements also reported.⁴ These data helped validate IGF-1R inhibition as a disease-modifying strategy in TED, while also highlighting the need to monitor class-associated toxicities.
Lumvoa’s differentiating regulatory feature, based on the company announcement, is labeling that includes data from both active and chronic TED populations.¹ That distinction may be clinically relevant because many patients present after the active inflammatory phase or continue to have persistent proptosis and diplopia despite low disease activity. However, cross-trial comparisons with teprotumumab or other approaches are not appropriate without head-to-head data.
References
